BR112022012286A2 - Combinações - Google Patents
CombinaçõesInfo
- Publication number
- BR112022012286A2 BR112022012286A2 BR112022012286A BR112022012286A BR112022012286A2 BR 112022012286 A2 BR112022012286 A2 BR 112022012286A2 BR 112022012286 A BR112022012286 A BR 112022012286A BR 112022012286 A BR112022012286 A BR 112022012286A BR 112022012286 A2 BR112022012286 A2 BR 112022012286A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- compounds
- condition
- inhibitor
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952042P | 2019-12-20 | 2019-12-20 | |
| US202063009754P | 2020-04-14 | 2020-04-14 | |
| PCT/US2020/065411 WO2021127046A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012286A2 true BR112022012286A2 (pt) | 2022-08-30 |
Family
ID=76478099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012286A BR112022012286A2 (pt) | 2019-12-20 | 2020-12-16 | Combinações |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230042653A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069224A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023507799A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220119428A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115103673A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020408698A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012286A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165477A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294084A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007624A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202135810A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127046A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5411847B2 (ja) * | 2007-04-25 | 2014-02-12 | Msd株式会社 | Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| CA2706946A1 (en) * | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| HRP20140821T1 (hr) * | 2009-09-15 | 2014-10-10 | Merck Sharp & Dohme Corp. | Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona |
| SMT201700595T1 (it) * | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| AU2016344040B2 (en) * | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US11932650B2 (en) * | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| EP3712150B1 (en) * | 2017-11-01 | 2024-06-12 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Macrocyclic compound serving as wee1 inhibitor and applications thereof |
| JP2022543832A (ja) * | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
-
2020
- 2020-12-16 EP EP20901854.8A patent/EP4069224A4/en active Pending
- 2020-12-16 AU AU2020408698A patent/AU2020408698A1/en not_active Abandoned
- 2020-12-16 US US17/757,511 patent/US20230042653A1/en not_active Abandoned
- 2020-12-16 WO PCT/US2020/065411 patent/WO2021127046A1/en not_active Ceased
- 2020-12-16 CN CN202080095319.0A patent/CN115103673A/zh active Pending
- 2020-12-16 KR KR1020227024839A patent/KR20220119428A/ko not_active Ceased
- 2020-12-16 MX MX2022007624A patent/MX2022007624A/es unknown
- 2020-12-16 BR BR112022012286A patent/BR112022012286A2/pt not_active IP Right Cessation
- 2020-12-16 IL IL294084A patent/IL294084A/en unknown
- 2020-12-16 CA CA3165477A patent/CA3165477A1/en active Pending
- 2020-12-16 JP JP2022538229A patent/JP2023507799A/ja active Pending
- 2020-12-18 TW TW109145166A patent/TW202135810A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4069224A4 (en) | 2023-12-20 |
| US20230042653A1 (en) | 2023-02-09 |
| JP2023507799A (ja) | 2023-02-27 |
| MX2022007624A (es) | 2022-08-16 |
| CA3165477A1 (en) | 2021-06-24 |
| TW202135810A (zh) | 2021-10-01 |
| CN115103673A (zh) | 2022-09-23 |
| IL294084A (en) | 2022-08-01 |
| KR20220119428A (ko) | 2022-08-29 |
| AU2020408698A1 (en) | 2022-07-14 |
| EP4069224A1 (en) | 2022-10-12 |
| WO2021127046A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012280A2 (pt) | Combinações | |
| BR112022012281A2 (pt) | Combinações | |
| BR112022012283A2 (pt) | Combinações | |
| BR112022012278A2 (pt) | Combinações | |
| BR112022023254A2 (pt) | Monoterapias e terapias de combinação | |
| BR112018074621A2 (pt) | derivados de pirazolopirimidina como inibidores de quinase | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| CU20180006A7 (es) | Compuestos de indazaol y azaindazol como inhibidores de irak-4 | |
| MX389450B (es) | Compuesto novedoso de pirimidina condensada o sal del mismo. | |
| BR112022012266A2 (pt) | Combinações | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
| BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
| BR112022010082A2 (pt) | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica | |
| MX385138B (es) | Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes. | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
| BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2020012253A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona para el tratamiento del carcinoma quistico adenoide. | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
| BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| BR112022009035A2 (pt) | Fármaco de combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2859 DE 21-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |